SGMT vs TROW · rev $2.0M vs P/E 12, rev $7.09B
Sagimet Biosciences Inc. Series A Common Stock (SGMT) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported SGMT revenue for 2023-09-30 was $2.0M. Net income was -$6.4M. Revenue was up 0.0% from 2023-07-31 to 2023-09-30. SGMT currently screens at market cap $403.2M.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
SGMT currently screens at market cap $403.2M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the SGMT and TROW stock pages for the full models.
Not investment advice.